Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00070031
First received: October 3, 2003
Last updated: December 18, 2013
Last verified: December 2009
  Purpose

RATIONALE: Drugs used in chemotherapy such as edotecarin use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well edotecarin works in treating women with locally advanced or metastatic breast cancer that has not responded to previous chemotherapy.


Condition Intervention Phase
Breast Cancer
Drug: edotecarin
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: June 2003
Study Completion Date: December 2009
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Determine the antitumor activity of edotecarin in women with anthracycline- and taxane-refractory or chemoresistant locally advanced or metastatic breast cancer.

Secondary

  • Determine the time to tumor response and duration of response in patients treated with this drug.
  • Determine the overall survival of patients treated with this drug.
  • Determine the clinical benefit of this drug in these patients.
  • Determine the safety and tolerability of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive edotecarin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months until disease progression.

PROJECTED ACCRUAL: A total of 31-65 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed primary adenocarcinoma of the breast

    • Locally advanced or metastatic disease
  • Not amenable to surgery or radiotherapy with curative intent
  • At least 1 unidimensionally measurable lesion

    • At least 20 mm by conventional techniques OR 10 mm by CT scan
    • Not previously irradiated
  • Meets 1 of the following criteria:

    • Previously treated with anthracycline and concurrent or sequential taxane therapy

      • Refractory to the most recent taxane-based chemotherapy, defined as 1 of the following:

        • Progressive disease during therapy or within 4 months of the last dose with or without documented response for advanced disease
        • Progressive disease within 6 months of completing taxane-based chemotherapy as neoadjuvant therapy
    • Resistant to prior chemotherapy, as defined by progressive disease within 6 months of completing prior chemotherapy for advanced disease
  • No known brain metastases or carcinomatous meningitis* NOTE: *Baseline CT scan or MRI of the brain required if there is clinical suspicion of CNS metastases
  • No spinal cord compression
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT no greater than 2.5 times ULN (5 times ULN if liver involvement secondary to tumor is present)
  • Albumin at least 3.0 g/dL

Renal

  • Creatinine no greater than 1.5 mg/dL

Cardiovascular

  • LVEF at least 50% or ULN by echocardiogram or MUGA
  • None of the following within the past 6 months:

    • Myocardial infarction
    • Severe or unstable angina
    • Symptomatic congestive heart failure
    • Cerebrovascular accident or transient ischemic attack
    • Deep vein thrombosis or other significant thromboembolic event
  • No ongoing cardiac dysrhythmias grade 2 or greater
  • No atrial fibrillation of any grade

Pulmonary

  • No pulmonary embolism within the past 6 months

Gastrointestinal

  • No active inflammatory bowel disease
  • No partial or complete bowel obstruction
  • No chronic diarrhea

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known HIV positivity
  • No active infection
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation or confound study results

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent biological response modifiers
  • No concurrent immunotherapy
  • No concurrent sargramostim (GM-CSF)
  • No other concurrent granulocyte colony-stimulating factors

Chemotherapy

  • See Disease Characteristics
  • Prior adjuvant chemotherapy allowed
  • No prior topoisomerase I inhibitors
  • No more than 2 prior chemotherapy regimens for advanced disease
  • No prior high-dose chemotherapy that required hematopoietic stem cell rescue
  • No other concurrent chemotherapy

Endocrine therapy

  • Prior adjuvant hormonal therapy or hormonal therapy for advanced/metastatic disease allowed provided that therapy is discontinued before study entry
  • No concurrent hormonal therapy

Radiotherapy

  • See Disease Characteristics
  • No prior radiotherapy to more than 25% of the bone marrow
  • No concurrent radiotherapy during and for 5 days after study treatment

    • Palliative radiotherapy allowed provided no more than 20% of the bone marrow is involved

Surgery

  • No coronary/peripheral artery bypass graft within the past 6 months

Other

  • Recovered from prior therapy (except alopecia or neurotoxicity)
  • At least 4 weeks since any other prior therapy
  • More than 4 weeks since prior investigational agents
  • No concurrent enrollment on another clinical trial
  • No other concurrent approved or investigational anticancer treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00070031

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Andrew D. Seidman, MD Memorial Sloan-Kettering Cancer Center
Principal Investigator: Clifford A. Hudis, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00070031     History of Changes
Other Study ID Numbers: CDR0000329917, MSKCC-03056, PHARMACIA-EDOABC-4439-001
Study First Received: October 3, 2003
Last Updated: December 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on August 28, 2014